Document:

WWW.EXFILE.COM -- PERFORMANCE HEALTH -- 16029 -- EXHIBIT 10-130 TO FORM 10-Q

    EXHIBIT
10.130

     

     

    THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).  THE SECURITIES MAY
NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR AN OPINION OF COUNSEL IN FORM,
SUBSTANCE AND SCOPE CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD PURSUANT TO RULE
144 UNDER SAID ACT.

     

    FORM
OF UNSECURED NON-CONVERTIBLE PROMISSORY NOTE

    
    

     

    
      	

              Trenton,
      New Jersey

              ___________,
      2008 

            	
              $________

            

    

     

                                                                                                                                  

    FOR VALUE RECEIVED, PERFORMANCE HEALTH TECHNOLOGIES,
INC., a Delaware corporation (hereinafter called the “Borrower”), hereby
promises to pay to the order of _________________or registered assigns (the
“Holder”) the sum of _________, on ________________, 2008 [180 days] (such date,
the “Maturity Date”), and to pay interest on the unpaid principal balance hereof
at the rate of twelve percent (12%) per annum from the date of this Note (the
“Issue Date”) until the same becomes due and payable, whether at maturity or
upon acceleration or by prepayment or otherwise.  Interest shall
commence accruing on the Issue Date, shall be computed on the basis of a 365-day
year and the actual number of days elapsed and shall be payable in cash on the
Maturity Date.

     

    All
payments due hereunder shall be made in cash at such address as the Holder shall
hereafter give to the Borrower by written notice made in accordance with the
provisions of this Note.

     

    Whenever
any amount expressed to be due by the terms of this Note is due on any day which
is not a business day, the same shall instead be due on the next succeeding day
which is a business day.  As used in this Note, the term “business
day” shall mean any day other than a Saturday, Sunday or a day on which
commercial banks in the city of New York, New York are authorized or required by
law or executive order to remain closed.  Each capitalized term used
herein, and not otherwise defined, shall have the meaning ascribed thereto in
that certain Subscription Agreement between the Holder and the Borrower to which
this Note relates, as amended from time to time, pursuant to which the Holder
subscribed to purchase this Note (the “Subscription Agreement”).

     

    This Note
is free from all taxes, liens, claims and encumbrances with respect to the issue
thereof and shall not be subject to preemptive rights or other similar rights of
shareholders of the Borrower and will not impose personal liability upon the
Holder thereof.

     

    The
following terms shall apply to this Note:

     

    1.           RIGHT
OF REDEMPTION

    

    A.           Optional
Redemption.  At any time prior to the Maturity Date the
Borrower at its option shall have the right, with ten (10)  business
days advance written notice (the “Optional Redemption Notice”), to redeem a
portion or all amounts outstanding under this Note in an amount equal to the
principal amount outstanding being redeemed and accrued interest thereon (the

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    “Optional
Redemption Amount”).  The Borrower shall deliver to the Holder the
Optional Redemption Amount on the tenth (10th)
business day after the Optional Redemption Notice (the “Optional Repayment
Date”).

    

    In the
event that the Borrower redeems a portion of the amount outstanding under this
Note, the Borrower shall be entitled to an off-set of the amount of principal
and accrued interest due equal to the amount of principal and accrued interest
redeemed.

    

    B.           Mandatory
Redemption.  At any time prior to the Maturity Date the
Borrower shall upon a Mandatory Redemption Event (as herein defined) have the
obligation, with ten (10)  business days advance written notice (the
“Mandatory Redemption Notice”), to redeem all amounts outstanding under this
Note in an amount equal to 100% of the principal amount outstanding and accrued
interest thereon (the “Mandatory Redemption Amount”).  The Borrower
shall deliver to the Holder the Mandatory Redemption Amount on the tenth
(10th)
business day after the Mandatory Redemption Notice.  The “Mandatory
Redemption Event” shall be defined as the date on which the Company has closed
upon equity financings grossing an aggregate of $1 million commencing upon the
Issue Date and ending upon the Maturity Date.

    

    2.            EVENTS
OF DEFAULT

    

    If any of
the following events of default (each, an “Event of Default”) shall
occur:

     

    A.           Failure to Pay Principal or
Interest.  The Borrower fails to pay the principal hereof or
interest thereon when due on this Note, whether at maturity, upon acceleration
or otherwise;

     

    B.           Receiver or
Trustee.  The Borrower or any subsidiary of the Borrower shall
make an assignment for the benefit of creditors, or apply for or consent to the
appointment of a receiver or trustee for it or for a substantial part of its
property or business, or such a receiver or trustee shall otherwise be
appointed;

     

    C.           Bankruptcy.  Bankruptcy,
insolvency, reorganization or liquidation proceedings or other proceedings for
relief under any bankruptcy law or any law for the relief of debtors shall be
instituted by or against the Borrower or any subsidiary of the Borrower which
remains unvacated, unbonded or unstayed for a period of thirty (30)
days;

     

    then,
upon the occurrence and during the continuation of any Event of Default
specified in Section 2.A, at the option of the Holders of a majority of the
aggregate principal amount of the outstanding Notes issued in connection with
the Offering pursuant to which this Note was issued, exercisable through the
delivery of written notice to the Borrower by such Holders (the “Default
Notice”), and upon the occurrence of an Event of Default specified in Section
2.B or C, the Notes shall become immediately due and payable (the “Mandatory
Prepayment Date”) and all amounts payable hereunder shall immediately become due
and payable, all without demand, presentment or notice, all of which hereby are
expressly waived, together with all costs, including, without limitation, legal
fees and expenses, of collection, and the Holder shall be entitled to exercise
all other rights and remedies available at law or in equity.

     

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    3.           MISCELLANEOUS

    

    A.           Failure or Indulgence Not
Waiver.  No failure or delay on the part of the Holder in the
exercise of any power, right or privilege hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise of any such power, right or
privilege preclude other or further exercise thereof or of any other right,
power or privileges.  All rights and remedies existing hereunder are
cumulative to, and not exclusive of, any rights or remedies otherwise
available.

     

    B.           Notices.  Any
notice herein required or permitted to be given shall be in writing and may be
personally served or delivered by courier or sent by United States mail and
shall be deemed to have been given upon receipt if personally served (which
shall include telephone line facsimile transmission) or sent by courier or three
(3) days after being deposited in the United States mail, certified, with
postage pre-paid and properly addressed, if sent by mail.  For the
purposes hereof, the address of the Holder shall be as shown on the records of
the Borrower; and the address of the Borrower shall be 427 River View Plaza,
Trenton, NJ 08611 facsimile number: (609) 656-0869.  Both the Holder
and the Borrower may change the address for service by service of written notice
to the other as herein provided.

     

    C.           Amendments.  This
Note and any provision hereof may only be amended by an instrument in writing
signed by the Borrower and the Holder.  The term “Note” and all
reference thereto, as used throughout this instrument, shall mean this
instrument as originally executed, or if later amended or supplemented, then as
so amended or supplemented.

     

    D.           Assignability.  This
Note shall be binding upon the Borrower and its successors and assigns, and
shall inure to be the benefit of the Holder and its successors and
assigns.  Each transferee of this Note must be an “accredited
investor” (as defined in Rule 501(a) of the Securities
Act).  Notwithstanding anything in this Note to the contrary, this
Note may be pledged as collateral in connection with a bona fide margin account
or other lending arrangement, subject to all applicable federal and state
securities laws.

     

    E.           Governing
Law.  THIS NOTE SHALL BE ENFORCED, GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE APPLICABLE TO AGREEMENTS MADE
AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICT OF LAWS.  THE BORROWER HEREBY SUBMITS TO THE EXCLUSIVE
JURISDICTION OF THE UNITED STATES FEDERAL COURTS LOCATED IN NEW YORK, NEW YORK
WITH RESPECT TO ANY DISPUTE ARISING UNDER THIS NOTE, THE AGREEMENTS ENTERED INTO
IN CONNECTION HEREWITH OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. BOTH
PARTIES IRREVOCABLY WAIVE THE DEFENSE OF AN INCONVENIENT FORUM TO THE
MAINTENANCE OF SUCH SUIT OR PROCEEDING.  BOTH PARTIES FURTHER AGREE
THAT SERVICE OF PROCESS UPON A PARTY MAILED BY FIRST CLASS MAIL SHALL BE DEEMED
IN EVERY RESPECT EFFECTIVE SERVICE OF PROCESS UPON THE PARTY IN ANY SUCH SUIT OR
PROCEEDING.  NOTHING HEREIN SHALL AFFECT EITHER PARTY’S RIGHT TO SERVE
PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.  BOTH PARTIES AGREE THAT
A FINAL NON-APPEALABLE JUDGMENT IN ANY SUCH SUIT OR PROCEEDING SHALL BE
CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON SUCH JUDGMENT
OR IN ANY OTHER LAWFUL MANNER.  THE PARTY WHICH DOES NOT PREVAIL IN
ANY DISPUTE ARISING UNDER THIS NOTE SHALL BE RESPONSIBLE FOR ALL FEES AND
EXPENSES, INCLUDING ATTORNEYS’ FEES, INCURRED BY THE PREVAILING PARTY IN
CONNECTION WITH SUCH DISPUTE.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    F.           Denominations.  At
the request of the Holder, upon surrender of this Note, the Borrower shall
promptly issue new Notes in the aggregate outstanding principal amount hereof,
in the form hereof, in such denominations of at least $1,000 as the Holder shall
request.

     

     G.           No Preemptive
Rights.  Except as provided herein no Holder of this Note shall
be entitled to rights to subscribe for, purchase or receive any part of any new
or additional shares of any class, whether now or hereinafter authorized, or of
bonds or Notes, or other evidences of indebtedness convertible into or
exchangeable for shares of any class, but all such new or additional shares of
any class, or any bond, Notes or other evidences of indebtedness convertible
into or exchangeable for shares, may be issued and disposed of by the Board of
Directors on such terms and for such consideration (to the extent permitted by
law), and to such person or persons as the Board of Directors in their absolute
discretion may deem advisable.

     

     IN WITNESS WHEREOF, Borrower
has caused this Note to be signed in its name by its duly authorized
officer.

    

    PERFORMANCE
HEALTH TECHNOLOGIES, INC.

    

    

    

    By: 
______________________________

           
Name:

           
Title:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        4WWW.EXFILE.COM -- PERFORMANCE HEALTH -- 16029 -- EXHIBIT 10-131 TO FORM 10-Q

    
      EXHIBIT
10.131

    

     

    THE SECURITIES REPRESENTED BY THIS
WARRANT CERTIFICATE AND THE SECURITIES ISSUABLE UPON
EXERCISE HEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”).  THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN
THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER SAID
ACT, OR AN OPINION OF COUNSEL IN FORM, SUBSTANCE AND SCOPE CUSTOMARY FOR
OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS THAT REGISTRATION IS NOT REQUIRED
UNDER SAID ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID
ACT.

     Dated:
_____________, 2008

    

    

    FORM OF WARRANT

    

    To
Purchase _____ shares of

    Common
Stock, $.01 par value

    

    of

    

    Performance
Health Technologies, Inc.

    

    Expiring
________________, 2013

    

    THIS IS
TO CERTIFY THAT, for value received, __________, or registered
assigns (hereinafter referred to as the “Holder”), is entitled to subscribe and
purchase from PERFORMANCE
HEALTH TECHNOLOGIES, INC., a Delaware corporation (the
“Company”), commencing on the date hereof, ______ shares of common stock, $.01
par value, of the Company (the “Shares”), at the place where the Warrant Agency
(as defined in Section 2.01 below) is located, at the Exercise Price (as
hereinafter defined), all subject to adjustment and upon the terms and
conditions as hereinafter provided, and is entitled also to exercise the other
appurtenant rights, powers and privileges hereinafter described; provided,
however, that in no event shall the Holder be entitled to exercise this Warrant
for a number of Shares in excess of that number of Shares which, upon giving
effect to such exercise, would cause the aggregate number of shares of Company
common stock beneficially owned by the Holder and its affiliates to exceed 9.99%
of the outstanding shares of the Company common stock following such exercise,
except within sixty (60) days of the expiration date of this
Warrant.  For purposes of the foregoing proviso, the aggregate number
of shares of common stock beneficially owned by the Holder and its affiliates
shall include the number of shares of common stock issuable upon exercise of
this Warrant with respect to which the application of such proviso is being
made, but shall exclude shares of common stock which would be issuable upon (i)
exercise of any remaining, unexercised warrants beneficially owned by the Holder
or its affiliates and (ii) exercise or conversion of the unexercised or
unconverted portion of any other securities of the Company beneficially owned by
the Holder or its affiliates (including, without limitation, any convertible
notes or preferred stock) subject to a limitation on conversion or exercise
analogous to the limitation contained herein.  Except as set forth in
the preceding sentence, for purposes of this paragraph, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended.  For purposes of this warrant, in determining
the number of outstanding shares of common stock of the Company, a Holder may
rely on the 

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

    number of
outstanding shares of common stock as reflected in (1) the Company’s most recent
Form 10-Q or Form 10-K, as the case may be, (2) a more recent public
announcement by the Company or (3) any other notice by the Company or its
transfer agent setting forth the number of shares of the Company’s common stock
outstanding.  Upon the written request of any Holder, the Company
shall promptly, but in no event later than one (1) Business Day following the
receipt of such notice, confirm in writing to any such Holder the number of
shares of the Company’s common stock then outstanding.  In any case,
the number of outstanding shares of the Company’s common stock shall be
determined after giving effect to the exercise of warrants (as defined below) by
such Holder or its affiliates since the date as of which such number of
outstanding shares of the Company’s common stock was reported.

     

    Capitalized
terms used in this Warrant and not otherwise defined shall have the meanings set
forth in Article IV hereof.

    

    ARTICLE
I

    EXERCISE
OF WARRANTS

    

    Section
1.01      Method of
Exercise.  To exercise this Warrant in whole or in part, the
Holder shall deliver to the Company at the Warrant Agency, (a) this Warrant, (b)
a written notice, in substantially the form of the Subscription Notice attached
hereto, of such Holder's election to exercise this Warrant, which notice shall
specify the number of Shares to be purchased, the denominations of the share
certificate or certificates desired and the name or names in which such
certificates are to be registered and (c) the aggregate Exercise Price for the
Shares purchased (unless the Holder chooses the "cashless exercise" option
provided in the third paragraph of this Section 1.01).

    

    The
Company shall, as promptly as practicable and in any event within seventy-two
hours thereafter, execute and deliver or cause to be executed and delivered, in
accordance with such notice, a certificate or certificates representing the
aggregate number of Shares specified in said notice.  The Share
certificate or certificates so delivered shall be in such denominations as
determined by the Company, or as may be specified in such notice, and shall be
issued in the name of the Holder or such other name or names as shall be
designated in such notice.  Such certificate or certificates shall be
deemed to have been issued, and such Holder or any other person so designated to
be named therein shall be deemed for all purposes to have become holders of
record of such Shares, as of the date the aforementioned notice is received by
the Company.  If this Warrant shall have been exercised only in part,
the Company shall, at the time of delivery of the certificate or certificates,
deliver to the Holder a new Warrant evidencing the rights to purchase the
remaining Shares called for by this Warrant, which new Warrant shall in all
other respects be identical with this Warrant, or, at the request of the Holder,
appropriate notation may be made on this Warrant which shall then be returned to
the Holder.  The Company shall pay all expenses, payable in connection
with the preparation, issuance and delivery of Share certificates and new
Warrants as contemplated by Section 2.07 below (other than transfer, income or
similar taxes in connection with the transfer of securities), except that, if
Share certificates or new Warrants shall be registered in a name or names other
than the name of the Holder, funds sufficient to pay all transfer taxes payable
as a result of such transfer shall be paid by the Holder at the time of
delivering the aforementioned notice of exercise or promptly upon receipt of a
written request of the Company for payment.

    

    In lieu
of a monetary payment of the aggregate Exercise Price, the Holder may elect to
receive, without the payment of any additional consideration, Shares equal to
the value of this 

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    Warrant
or portion thereof by the surrender of such Warrant to the Company with the
"cashless exercise" election marked in the form of Subscription
Notice.  Thereupon, the Company shall issue to the Holder, such number
of fully paid and non-assessable Shares as is computed using the following
formula:

    

     X  =
Y(A-B)

             A

    
    

    

    
      	

              Where

            	

              X=

            	

              the
      number of Shares to be issued to the Holder pursuant to this Section
      1.01  upon such cashless exercise election.

            
	 	 	 
	
               
      

            	
              Y=

            	
              the
      number of Shares covered by this Warrant in respect of which the cashless
      exercise election is made.

            

    

    

    
      	
               
      

            	
              A=

            	
              the
      Fair Market Value (as defined in Article IV hereof) of one Share, as at
      the time the cashless exercise election is
made.

            

    

    

    
      	
               
      

            	
              B=

            	
              the
      Exercise Price in effect under this Warrant at the time the cashless
      exercise election is made.

            

    

    

    Section
1.02      Shares To Be Fully Paid and
Non-assessable.  All Shares issued upon the exercise of this
Warrant (the "Warrant Shares") pursuant to Section 1.01 above shall be validly
issued, fully paid and nonassessable and the Company shall at all times reserve
and keep available out of its authorized shares of common stock a sufficient
number of Shares for the purpose of issuance of the Warrant Shares upon the
exercise of this Warrant.

    

    Section
1.03      No Fractional Shares To Be
Issued.  The Company shall not be required to issue fractions
of Shares upon exercise of this Warrant.  If any fraction of a Share
would, but for this Section, be issuable upon any exercise of this Warrant, in
lieu of such fractional Share the Company shall pay to the Holder or Holders, as
the case may be, in cash, an amount equal to the same fraction of the Fair
Market Value per share of outstanding Shares on the Business Day immediately
prior to the date of such exercise.

    

    Section
1.04      Share
Legend.  Each certificate for Shares issued upon exercise of
this Warrant shall bear the legend set forth below, unless Holder's Counsel (as
defined below) shall render an opinion in form and substance reasonably
satisfactory to the Company that such legend is not required or at the time of
exercise such Shares are registered under the Securities Act:

    

    THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”).  THE SECURITIES MAY NOT BE SOLD, TRANSFERRED OR
ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER SAID ACT, OR AN OPINION OF COUNSEL IN FORM, SUBSTANCE AND SCOPE
CUSTOMARY FOR OPINIONS OF COUNSEL IN COMPARABLE TRANSACTIONS THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID
ACT.

    

    Any
certificate issued at any time in exchange or substitution for any certificate
bearing such legend (except a new certificate issued upon completion of a public
distribution pursuant to a registration statement under the Securities Act)
shall also bear such legend unless, in the opinion (in form and substance
reasonably satisfactory to the Company) of counsel selected by the Holder of
such certificate and who is reasonably acceptable to the Company ("Holder's
Counsel"), the securities represented thereby need no longer be subject to
restrictions on resale under the Securities Act.

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    ARTICLE
II

    WARRANT
AGENCY; TRANSFER,

    EXCHANGE
AND REPLACEMENT OF WARRANTS

    

    Section
2.01      Warrant
Agency.  Until such time, if any, as an independent agency
shall be appointed by the Company to perform services with respect to the
Warrants described herein (the "Warrant Agency"), the Company shall perform the
obligations of the Warrant Agency provided herein at its principal office
address or such other address as the Company shall specify by prior written
notice to all Holders.

    

    Section
2.02      Ownership of
Warrant.  The Company may deem and treat the person in whose
name this Warrant is registered as the holder and owner hereof (notwithstanding
any notations of ownership or writing hereon made by any person other than the
Company) for all purposes and shall not be affected by any notice to the
contrary, until presentation of this Warrant for registration of transfer as
provided in this Article II.

    

    Section
2.03      Transfer of
Warrant.  The Company agrees to maintain at the Warrant Agency
books for the registration of transfers of this Warrant and all rights hereunder
shall be registered, in whole or in part, on such books, upon surrender of this
Warrant at the Warrant Agency, together with a written assignment of this
Warrant duly executed by the Holder or its duly authorized agent or
attorney.  Subject to applicable law and regulation and Section 2.04
hereof, upon surrender of this Warrant as provided for herein, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees and in the denominations specified in the instrument of assignment,
and this Warrant shall promptly be canceled.  Notwithstanding the
foregoing, a Warrant may be exercised by a new Holder which has become the
registered Holder of such Warrant without having a new Warrant
issued.

     

    Section
2.04      Restrictions on
Transfer.  The Holder, by its acceptance hereof, represents
that this Warrant is being acquired for its own account, as an investment and
not with a view towards the further resale or the distribution thereof in
violation of the Securities Act, and agrees that this Warrant may not be
transferred, sold, assigned, hypothecated or otherwise disposed of, in whole or
in part, except as provided in the legend on the first page hereof and provided
that the Holder shall have furnished to the Company an opinion of Holder's
Counsel, in form and substance reasonably satisfactory to the Company, to the
effect that such transfer is exempt from the registration requirements of the
Securities Act and any applicable state securities laws.

     

    Section
2.05      Division or Combination of
Warrants.  This Warrant may be divided or combined with other
Warrants upon surrender hereof and of any Warrant or Warrants with which this
Warrant is to be combined at the Warrant Agency, together with a written notice
specifying the names and denominations in which the new Warrant or Warrants are
to be issued, signed by the holders hereof and thereof or their respective duly
authorized agents or attorneys.  Subject to compliance with Section
2.04 as to any transfer which may be involved in the division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for
the Warrant or Warrants to be divided or combined in accordance with such
notice.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    Section
2.06      Loss, Theft, Destruction of
Warrant Certificates.  Upon receipt by the Company of a written
notice (or other evidence reasonably satisfactory to the Company) of the loss,
theft, destruction or mutilation of any Warrant and, in the case of any such
loss, theft or destruction, upon receipt of indemnity or security reasonably
satisfactory to the Company or, in the case of any such mutilation, upon
surrender and cancellation of such Warrant, the Company will make and deliver,
in lieu of such lost, stolen, destroyed or mutilated Warrant, a new Warrant of
like tenor and representing the right to purchase the same aggregate number of
Shares.

     

    Section
2.07      Expenses of Delivery of
Warrants.  The Company shall pay all expenses (other than
transfer taxes) and other charges payable in connection with the preparation,
issuance and delivery of Warrants and Warrant Shares hereunder.

    

    ARTICLE
III

    COMPANY
COVENANTS AND REPRESENTATIONS

     

    Section
3.01       Company
Covenants.  In case at any time the Company shall (a) declare
any dividend or distribution on its Shares, whether payable in cash, stock or
other property, (b) offer to all holders of Shares any additional shares of
common stock, or any option, right or warrant to subscribe therefore, or (c)
declare a dissolution, liquidation or winding up of the Company (other than in
connection with a consolidation or merger) or propose a sale of substantially
all of its property, assets and business as an entirety, then the Company shall
give written notice to the Holder of the date on which the books of the Company
shall close or a record shall be taken for such action.  Such notice
shall also specify the date as of which the holders of Shares of record shall
participate in such dividend or distribution.  Such written notice
shall be given at least 30 days and not more than 90 days prior to the action in
question, and not less than 15 days prior to the relevant record date or the
date fixed for determining stockholders entitled to participate therein, as the
case may be.

    

    Section
3.02      Authority, Execution and
Delivery.  The Company hereby represents and warrants that the
Company has full corporate power and authority to enter into this Warrant and to
issue Shares in accordance with the terms hereof.  The execution,
delivery and performance of this Warrant by the Company have been duly and
effectively authorized by the Company.  This Warrant has been duly
executed and delivered by the Company and constitutes the legal, valid and
binding obligation of the Company enforceable against the Company in accordance
with its terms.

    

    Section
3.03      Information
Requirements.  To the extent applicable, the Company shall
promptly furnish the Holder with copies of all reports, proxy statements and
similar materials that it mails to holders of its common stock.

    

    ARTICLE
IV

    CERTAIN
DEFINITIONS

    

    The
following terms, as used in this Warrant, have the following respective
meanings:

    

    "Business
Day" means each day in which banking institutions in New York are not required
or authorized by law or executive order to close.

     

    "Exercise
Price" means $0.30 per share, subject to adjustment pursuant to Article
V.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     “Fair
Market Value” means the value of a share of common stock on a particular date,
determined as follows: (i) if the common stock is not listed on such date on any
national securities exchange but is traded in the over-the-counter market, the
closing "bid" quotations of a share of common stock on such date (or if none, on
the most recent date on which there were bid quotations of a share of common
stock), as reported on the National Association of Securities Dealers, Inc.
Automated Quotation System, or, if not so reported, as reported by the National
Quotation Bureau, Incorporated, or any other similar service selected by the
Board; or (ii) if the common stock is listed on such date on one or more
national securities exchanges, the last reported sale price of a share of common
stock on such date as recorded on the composite tape system, or, if such system
does not cover the common stock, the last reported sale price of a share of
common stock on such date on the principal national securities exchange on which
the common stock is listed, or if no sale of common stock took place on such
date, the last reported sale price of a share of common stock on the most recent
day on which a sale of a share of common stock took place as recorded by such
system or on such exchange, as the case may be; or (iii) if the common stock is
neither listed on such date on a national securities exchange nor traded in the
over-the-counter market, as determined by the Company.

    

    ARTICLE
V

    ANTIDILUTION
PROVISIONS

    

    Section 5.01    
Adjustments
Generally.  The Exercise Price and the number of Shares (or
other securities or property) issuable upon exercise of this Warrant shall be
subject to adjustment from time to time upon the occurrence of certain events,
as provided in this Article V.

    

    Section
5.02      Share
Reorganization.  If the Company shall subdivide its outstanding
Shares into a greater number of Shares or consolidate its outstanding Shares
into a smaller number of Shares (any such event being called a "Share
Reorganization"), then (a) the Exercise Price shall be adjusted,
effective immediately after the record date at which the holders of Shares are
determined for purposes of such Share Reorganization, to a price determined by
multiplying the Exercise Price in effect immediately prior to such record date
by a fraction, the numerator of which shall be the number of Shares outstanding
on such record date before giving effect to such Share Reorganization and the
denominator of which shall be the number of Shares outstanding immediately after
giving effect to such Share Reorganization, and (b) the number of Shares subject
to purchase upon exercise of this Warrant shall be adjusted, effective at such
time, to a number determined by multiplying the number of Shares subject to
purchase immediately before such Share Reorganization by a fraction, the
numerator of which shall be the number of Shares outstanding immediately after
giving effect to such Share Reorganization and the denominator of which shall be
the number of Shares outstanding immediately before such Share
Reorganization.

    

    Section
5.03      Below Market
Distribution.

    

    (a)  If the Company shall
issue or otherwise sell or distribute any Shares, other than pursuant to a Share
Reorganization (any such event, including any event described in paragraphs (c)
and (d) below, being herein called a "Below-Market
Distribution") for a consideration per share less than the Exercise Price
per Share on the date of such issue, sale or distribution (before giving effect
to such issue, sale or distribution), then, effective upon such issue, sale or
distribution, the Exercise Price shall be reduced to the price determined by
multiplying the Exercise Price in effect immediately prior to such Below-Market
Distribution by a fraction, the numerator of which shall be the sum of (i) the
number of Shares outstanding immediately prior to such Below-Market

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    Distribution
multiplied by the Exercise Price per share on the date of such Below-Market
Distribution plus (ii) the consideration received by the Company upon such
Below-Market Distribution, and the denominator of which shall be the product of
(A) the total number of Shares outstanding immediately after such Below-Market
Distribution, multiplied by (B) the Exercise Price per share on the date of such
Below-Market Distribution.  If any Below-Market Distribution shall
require an adjustment to the Exercise Price pursuant to the foregoing provisions
of this paragraph (a), then effective at the time such adjustment is made, the
number of Shares subject to purchase upon exercise of this Warrant shall be
increased to a number determined by multiplying the number of Shares subject to
purchase immediately before such Below-Market Distribution by a fraction, the
numerator of which the numerator of which shall be the Exercise Price in effect
immediately before such Below-Market Distribution and the denominator of which
shall be the Exercise Price in effect immediately after such Below-Market
Distribution.

    

    (b)           The
provisions of paragraph (a) above, including by operation of paragraph (c) or
(d) below, shall not operate to increase the Exercise Price or reduce the number
of shares of Shares subject to purchase upon exercise of this
Warrant.  The provisions of paragraph (a) above, including operation
of paragraph (c) or (d) below, shall not apply to the issuance of any Shares,
the issuance of or exercise of any options, warrants, or other rights, the
conversion of any debt or any other convertible security (collectively,
“Securities”) to the extent (i) now or hereafter issued or granted pursuant to
the Company’s Incentive Stock Plan as in effect on May 19, 2008, (ii) issued in
connection with any of the Company’s Securities outstanding on the date hereof,
or (iii) arising under transactions or agreements of the Company prior to May
19, 2008.

    

    (c)           If
the Company shall issue, sell, distribute or otherwise grant in any manner
(whether directly or by assumption in a merger or otherwise) any rights to
subscribe for or to purchase, or any warrants or options for the purchase of,
Shares or any stock or securities convertible into or exchangeable for Shares
(such rights, warrants or options being herein called "Options" and such
convertible or exchangeable stock or securities being herein called "Convertible
Securities"), whether or not such Options or the rights to convert or
exchange any such Convertible Securities are immediately exercisable, and the
price per share for which securities are issuable upon exercise of such Options
or upon conversion or exchange of such Convertible Securities (determined by
dividing (i) the aggregate amount, if any, received or receivable by the Company
as consideration for the granting of such Options, plus the minimum aggregate
amount of additional consideration payable to the Company upon the exercise of
all such Options, plus, in the case of Options to acquire Convertible
Securities, the minimum aggregate amount of additional consideration, if any,
payable upon the issue or sale of such Convertible Securities and upon the
conversion or exchange thereof, by (ii) the total maximum number of Shares
issuable upon the exercise of such Options or upon the conversion or exchange of
all such Convertible Securities issuable upon the exercise of such Options)
shall be less than the Exercise Price per share of outstanding Shares on the
date of granting such Options (before giving effect to such grant), then, for
purposes of paragraph (a) above, the total maximum number of Shares issuable
upon the exercise of such Options or upon conversion or exchange of the
Convertible Securities issuable upon the exercise of such Options shall be
deemed to have been issued as of the date of granting of such Options and
thereafter shall be deemed to be outstanding and the Company shall be deemed to
have received as consideration such price per share, determined as
provided  above, therefor.  Except as otherwise provided in
paragraph (e) below, no additional adjustment of the Exercise Price shall be
made upon the actual exercise of such Options or upon conversion or exchange of
such Convertible Securities.  The adjustment provided for in this
paragraph (c) shall give effect to the change in the Exercise Price and the
number of Shares issuable upon the exercise hereof only with respect to such
Options as remain outstanding.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    (d)           If
the Company shall issue, sell or otherwise distribute (whether directly or
otherwise) any Convertible Securities, whether or not the rights to exchange or
convert thereunder are immediately exercisable, and the price per share for
which Shares are issuable upon such conversion or exchange (determined by
dividing (i) the aggregate amount received or receivable by the Company as
consideration for the issue, sale or distribution of such Convertible
Securities, plus the minimum aggregate amount of additional consideration, if
any, payable to the Company upon the conversion or exchange thereof, by (ii) the
total maximum number of Shares issuable upon the conversion or exchange of all
such Convertible Securities) shall be less than the Exercise Price per share of
outstanding Shares on the date of such issue, sale or distribution (before
giving effect to such issue, sale or distribution), then, for purposes of
paragraph (a) above, the total maximum number of Shares issuable upon conversion
or exchange of all such Convertible Securities shall be deemed to have been
issued as of the date of the issue, sale or distribution of such Convertible
Securities and thereafter shall be deemed to have received as consideration such
price per share, determined as provided above, therefor.  Except as
otherwise provided in paragraph (e) below, no additional adjustment of the
Exercise Price shall be made upon the actual conversion or exchange of such
Convertible Securities.

    

    (e)           If
the purchase price provided for in any Option referred to in paragraph (c)
above, the additional consideration, if any, payable upon the conversion or
exchange of any Convertible Securities referred to in paragraph (c) or (d)
above, or the rate at which any Convertible Securities referred to in paragraph
(c) or (d) above are convertible into or exchangeable for Shares shall change at
any time (other than under or by reason of provisions designed to protect
against dilution upon an event which results in a related adjustment pursuant to
this Article V), including the cancellation and/or expiration or termination of
the Options and/or Convertible Securities, the Exercise Price then in effect
shall forthwith be readjusted (effective only with respect to any exercise of
this Warrant after such readjustment) to the Exercise Price which would then be
in effect had the adjustment made upon the issue, sale, distribution or grant of
such Options or Convertible Securities been made based upon such changed
purchase price, additional consideration or conversion rate, or in the event of
the cancellation, termination or expiration of the same, such adjustment shall
be made to reflect as if such issuance had never occurred, as the case may be;
provided, however, that such
readjustment (other than in the event of a cancellation, termination or
expiration) shall give effect to such change only with respect to such Options
and Convertible Securities as then remain outstanding.

    

    (f)           If
the Company shall pay a dividend or make any other distribution upon any capital
stock of the Company payable in Shares, Options or Convertible Securities, then,
for purposes of paragraph (a) above, such Shares, Options or Convertible
Securities, as the case may be, shall be deemed to have been issued or sold
without consideration.

    

    (g)           If
any Shares, Options or Convertible Securities shall be issued, sold or
distributed for cash, the consideration received therefor shall be deemed to be
the amount received by the Company therefor, after deduction therefrom of any
expenses incurred and any underwriting commission or concessions paid or allowed
by the Company in connection therewith.  If any Shares, Options or
Convertible Securities shall be issued, sold or distributed for a consideration
other than cash, the amount of the consideration other than cash received by the
Company for purposes of this Section 5.03 shall be deemed to be the Fair Market
Value of such consideration, after deduction of any expenses incurred and any
underwriting commissions or concessions paid or allowed by the Company in
connection therewith.  If any Shares, Options or Convertible
Securities shall be issued in connection with any merger in which the Company is
the surviving corporation, the amount of 

     

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    consideration
therefor shall be deemed to be the Fair Market Value of such portion of the
assets and business of the nonsurviving corporation as shall be attributable to
such Shares, Option or Convertible Securities, as the case may be.  If
any Options shall be issued in connection with the issue and sale of other
securities of the Company, together comprising one integral transaction in which
no specific consideration is allocated to such Options by the parties thereto,
such Options shall be deemed to have been issued without
consideration.

    

    Section
5.04      Special
Dividends.  If the Company shall issue or distribute to any
holders of Shares, evidences of indebtedness, any other securities of the
Company or any cash, property or other assets, and if such issuance or
distribution does not constitute (a) a cash dividend or distribution out of
surplus or net profits legally available therefor; (b) a Share Reorganization;
or (c) a Below Market Distribution  (any such nonexcluded event being
herein called a "Special Dividend"),
then (i) the Exercise Price shall be decreased, effective immediately after the
record date at which the holders of Shares are determined for purposes of such
Special Dividend, to a price determined by multiplying the Exercise Price then
in effect by a fraction, the numerator of which shall be the Exercise Price per
share of outstanding Shares on such record date less the then Fair Market Value
of the evidences of indebtedness, securities or property or other assets issued
or distributed in such Special Dividend with respect to one Share, and the
denominator of which shall be the Exercise Price per share on such record date,
and (ii) the number of Shares subject to purchase upon exercise of this Warrant
shall be increased to a number determined by multiplying the number of Shares
subject to purchase immediately before such Special Dividend by a fraction, the
numerator of which shall be the Exercise Price in effect immediately before such
Special Dividend and the denominator of which shall be the Exercise Price in
effect immediately after such Special Dividend.

    

    Section
5.05      Merger, Consolidation, Asset
Sale, Capital Reorganization.  If there shall be any
consolidation or merger to which the Company is a party, other than a
consolidation or a merger in which the Company is a continuing corporation and
which does not result in any reclassification of, or change (other than a Share
Reorganization or a change in nominal value) in, outstanding Shares, or any sale
or conveyance of the property of the Company as an entirety or substantially as
an entirety (any such event being called a "Capital
Reorganization"), then, effective upon the effective date of such Capital
Reorganization, the Holder shall have the right to purchase, upon exercise of
this Warrant, the kind and amount of shares of stock and other securities and
property (including cash) which the Holder would have owned or have been
entitled to receive after such Capital Reorganization if this Warrant had been
exercised immediately prior to such Capital Reorganization and this Warrant
shall expire.

    

    Section
5.06    Certain Other
Events.  If any event occurs as to which the foregoing
provisions of this Article V are not strictly applicable or, if strictly
applicable, would not, in the good faith judgment of the Board of Directors of
the Company, fairly protect the purchase rights of the Warrants in accordance
with the essential intent and principles of such provisions or would violate
applicable law, then such Board shall make such adjustments in the application
of such provisions (or if necessary make alternative provisions including taking
all reasonable efforts to amend the Company's organizational documents), in
accordance with such essential intent and principles, as shall be reasonably
necessary, in the good faith opinion of such Board, to protect such purchase
rights as aforesaid, but in no event shall any such adjustment have the effect
of increasing the Exercise Price or decreasing the number of  Shares
subject to purchase upon exercise of this Warrant.

    

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    

    Section
5.07          Adjustment
Rules.

    

    (a)           Any
adjustments pursuant to this Article V shall be made successively whenever an
event referred to herein shall occur.

    

    (b)           If
the Company shall set a record date to determine the holders of Shares for
purposes of a Share Reorganization, Below Market Distribution, Special Dividend
or Capital Reorganization and shall legally abandon such action prior to
effecting such action, then no adjustment shall be made pursuant to this Article
V in respect of such action.

    

    (c)           No
adjustment of the Exercise Price or number of Warrant Shares issuable upon
exercise hereof shall be made in an amount less than 1% of such Exercise Price
or number of Warrant Shares so issuable upon exercise hereof, respectively, but
any such lesser adjustment shall be carried forward and shall be made at the
time and together with the next subsequent adjustment which together with any
adjustments so carried forward shall amount to 1% or more of such Exercise Price
or number of Warrant Shares so issuable upon exercise,
respectively.

    

    Section
5.08         Proceeding Prior to Any
Action Requiring Adjustment.  As a condition precedent to the
taking of any action which would require an adjustment pursuant to this Article
V, the Company shall take any action which may be reasonably necessary,
including obtaining regulatory approvals or exemptions, in order that the
Company may thereafter validly and legally issue as fully paid and nonassessable
all Shares which the holders of Warrants are entitled to receive upon exercise
thereof.

    

    Section
5.09          Notice of
Adjustment.  Not less than 30 nor more than 90 days prior to
the effective date or 15 days prior to the record date, as the case may be, of
any action which requires or might require an adjustment or readjustment
pursuant to this Article V, the Company shall give notice to the Holder of such
event, describing such event in reasonable detail and specifying the record date
or effective date, as the case may be, and, if determinable, the required
adjustment and the computation thereof.  If the required adjustment is
not determinable at the time of such notice, the Company shall give notice to
the Holder of such adjustment and computation promptly after such adjustment
becomes determinable.

    

    ARTICLE
VI

    MISCELLANEOUS

    

    Section
6.01          Notices.  Any
notice or other communication to be given hereunder shall be in writing and
shall be delivered by recognized courier, telecopy or certified mail, return
receipt requested, and shall be conclusively deemed to have been received by a
party hereto and to be effective on the day on which delivered or telecopied to
such party at its address set forth below (or at such other address as such
party shall specify to the other parties hereto in writing), or, if sent by
certified mail, on the third business day after the day on which mailed,
addressed to such party at such address.  In the case of the Holder,
such notices and communications shall be addressed to its address as shown on
the books maintained by the Warrant Agency, unless the Holder shall notify the
Company and the Warrant Agency that notices and communications should be sent to
a different address, in which case such notices and communications shall be sent
to the address specified by the Holder, and in either case a copy of such
notices and communications shall be sent to Thomas P. Gallagher, Gallagher,
Briody & Butler, 155 Village Boulevard, Princeton, New Jersey 08540 Fax:
(609) 454-0090.  In the case of the Company, such notices and
communications shall be addressed as follows (until notice of a change is given
as provided herein): Performance Health Technologies, Inc., 427 River View
Plaza, Trenton, New Jersey 08611, Attention:  Robert Prunetti,
Fax:  (609) 656-0869.

    

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    Section
6.02        Waivers;
Amendments.  No failure or delay of the Holder in exercising
any power or right hereunder shall operate as a waiver thereof, nor shall any
single or partial exercise of such right or power, or any abandonment or
discontinuance of steps to enforce such a right or power, preclude any other or
further exercise thereof or the exercise of any other right or
power.  The rights and remedies of the Holder are cumulative and not
exclusive of any rights or remedies which it would otherwise
have.  The provisions of this Warrant may be amended, modified or
waived with (and only with) the written consent of the Company and Holders
holding a majority of Warrants issued as part of the Offering pursuant to which
this Warrant was issued at the time outstanding (or any permitted transferee of
all of the Warrant).  In the event of any such amendment, modification
or waiver the Company shall give prompt notice thereof to all Holders of such
Warrants and, if appropriate, notation thereof shall be made on all Warrants
thereafter surrendered for registration of transfer or exchange.  No
notice or demand on the Company in any case shall entitle the Company to any
other or further notice or demand in similar or other
circumstances.

     

    Section
6.03         Governing
Law.  This Warrant shall be construed in accordance with and
governed by the laws of the State of Delaware without regard to choice of law
doctrine.

     

    Section
6.04         Covenants To Bind Successor
and Assigns.  All covenants, stipulations, promises and
agreements in this Warrant contained by or on behalf of the Company shall bind
its successors and assigns, whether so expressed or not.

     

    Section
6.05         Severability.  In
case any one or more of the provisions contained in this Warrant shall be
invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein and therein shall
not in any way be affected or impaired thereby.  The parties shall
endeavor in good faith negotiations to replace the invalid, illegal or
unenforceable provisions with valid provisions the economic effect of which
comes as close as possible to that of the invalid, illegal or unenforceable
provisions.

     

    Section
6.06          Section
Headings.  The section headings used herein are for convenience
of reference only, are not part of this Warrant and are not to affect the
construction of or be taken into consideration in interpreting this
Warrant.

    

    Section
6.07          No Rights as
Stockholder.  This Warrant shall not entitle the Holder to any
rights as a stockholder of the Company.

    

    Section
6.08          No Requirement to
Exercise.  Nothing contained in this Warrant shall be construed
as requiring the Holder to exercise this Warrant.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed in its
corporate name by one of its officers thereunto duly authorized, and attested by
its Secretary or an Assistant Secretary, all as of the day and year first above
written.

     

     

     

     

    

     PERFORMANCE
HEALTH TECHNOLOGIES, INC.

    
 

    

     By:__________________________________________

     Name:

     Title:

    

    

    ATTESTED TO:

    

    

    By:__________________________________________

     Name:

     Title:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    SUBSCRIPTION
NOTICE

     

    (To be
executed upon exercise of Warrant)

     

    
 

    To:  Performance
Health Technologies, Inc. (the "Company")

    

    The
undersigned hereby irrevocably elects:

    

    (i) to
exercise the right of purchase represented by the attached Warrant for, and to
purchase thereunder, __________ Shares, as provided for therein, and tenders
herewith payment of the Exercise Price in full in the form of certified or bank
cashier's check or wire transfer; or

    

    (ii) the
"cashless exercise" of its rights under the Section 1.01 of the attached Warrant
with respect to ___________ Shares otherwise available for purchase to it under
the Warrant and to receive such number of Shares as provided in the formula set
forth in such Section 1.01.

    

    Please
issue a certificate or certificates for such Shares in the following name or
names and denominations:

     

    
      

    

     

    
      
        

      

       

    

    In
connection with the exercise of the Warrant, the undersigned hereby represents
and warrants that:

    

    (i) it
recognizes that the Shares issuable pursuant to the attached Warrant have not
been registered under the Securities Act and may not be sold, pledged or
otherwise transferred except pursuant to the exceptions set forth on the legend
on such Shares which is also set forth in Section 1.04 of the attached
Warrant;

    

    (ii) it
has received all material information with respect to the Company which it deems
necessary to make its decision to exercise the attached Warrant and it has been
given an opportunity to ask questions and receive answers from representatives
of the Company;

    

    (iii) it
is purchasing the Shares for its own account, for the purpose of investment
only, and not with a view towards the further resale or distribution thereof;
and

    

    (iv) it
is an "Accredited Investor" within the meaning of Rule 501 of Regulation D under
the Securities Act of 1933, as amended.

    

    If said
number of Shares shall not be all the Shares issuable upon exercise of the
attached Warrant, a new Warrant is to be issued in the name of the undersigned
for the balance remaining of such Shares less any fraction of a Share paid in
cash.

     

     By:
____________________________

     Name:
__________________________

     Its:_____________________________

     Dated:
__________________________

    

    NOTE:   The
above signatory should correspond exactly with the name on the face of the
attached Warrant or with the name of the assignee appearing in the assignment
form below.

     

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    ASSIGNMENT

    

    (To be
executed upon assignment of Warrant)

    

     

    For value
received and in accordance with Section 2.03 of the attached Warrant,
____________________ hereby sells, assigns and transfers unto
___________________________ the attached Warrant, together with all right, title
and interest therein, and does hereby irrevocably constitute and appoint
__________________ attorney to transfer said Warrant on the books of Performance
Health Technologies, Inc. with full power of substitution in the
premises.

     

    

     

    By:
___________________________

     Name:
____________________

      Its:
___________________________

     Dated:____________________

     

    
 

    
      	
               
      

            	
              NOTE:  The
      above signatory should correspond exactly with the name on the face of the
      attached Warrant.

            

    

    

     

    Consented
to and approved in accordance with

    Section
2.03 of the attached Warrant

    

    PERFORMANCE
HEALTH TECHNOLOGIES, INC.

    

    

    By: _________________________________

    Name:
________________________

    Its:
__________________________

    

    

    

    

    

    

    

    

    

    

    

    
      
        
        

      

      
        14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]